Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03826472 · ClinicalTrials.gov registry record · Phase 2
Almond Butter and Fasting Glucose
A Phase 2 study of Type 2 Diabetes, sponsored by Penn State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03826472: Completed Phase 2 study of Type 2 Diabetes, sponsored by Penn State University.
NCT03826472 is a Phase 2 study of Type 2 Diabetes that has completed, run by Penn State University. The registered enrollment target is 10 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03826472, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
A two-period randomized crossover study will be conducted to determine the effect of almond butter as an evening snack on fasting blood glucose in adults with type 2 diabetes, not taking insulin.
Primary Outcome
Fasting glucose measures how much glucose (sugar) is in a blood sample after an overnight fast. In this study, fasting glucose was measured by continuous glucose monitoring (interstitial glucose); fasting window identified through review of glucose monitoring data to be 4am-6am.
Conditions Studied
Interventions
- OTHER Almond Butter
Study Locations (1)
Pennsylvania
- Penn State - University Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-03-08 |
| Est. Completion | 2020-03-01 |
| Phase | Phase 2 |
What the finished NCT03826472 record still lists
NCT03826472 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Almond Butter is the first listed.
NCT03826472 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03826472 about?
NCT03826472 is a clinical study titled "Almond Butter and Fasting Glucose". A two-period randomized crossover study will be conducted to determine the effect of almond butter as an evening snack on fasting blood glucose in adults with type 2 diabetes, not taking insulin.
What is the current status of trial NCT03826472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-03-08. Estimated completion is 2020-03-01.
What conditions does trial NCT03826472 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT03826472?
The interventions under investigation include: Almond Butter (OTHER).
Who is sponsoring clinical trial NCT03826472?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03826472 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03826472's enrollment target sits among peer trials
10 321st of 327 higher than 4 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI